Overview

Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with everolimus may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus, carboplatin, and etoposide in treating patients with small cell lung cancer or other advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, Davis
Collaborator:
Novartis
Treatments:
Carboplatin
Etoposide
Etoposide phosphate
Everolimus
Sirolimus